




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Young, S., Absoud, M., Blackburn, C., Branney, P., Colley, B., Farrag, E., ... Mukherjee, R. (2016). Guidelines
for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal
alcohol spectrum disorders based upon expert consensus. BMC Psychiatry, 16(1), [324]. 10.1186/s12888-016-
1027-y
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
RESEARCH ARTICLE Open Access
Guidelines for identification and treatment
of individuals with attention deficit/
hyperactivity disorder and associated fetal
alcohol spectrum disorders based upon
expert consensus
Susan Young1,2*, Michael Absoud3, Carolyn Blackburn4, Polly Branney5, Bill Colley6, Emad Farrag7, Susan Fleisher8,
Ges Gregory9, Gisli H. Gudjonsson10, Keira Kim11, Kieran D. O’Malley12,13, Moira Plant14,15, Alina Rodriguez1,19,
Susan Ozer16, Inyang Takon17, Emma Woodhouse10 and Raja Mukherjee18
Abstract
Background: The association of attention deficit/hyperactivity disorder (ADHD) and fetal alcohol spectrum
disorders (FASD) results in a complex constellation of symptoms that complicates the successful diagnosis and
treatment of the affected individual. Current literature lacks formal guidelines, randomized control trials, and
evidence-based treatment plans for individuals with ADHD and associated FASD. Therefore, a meeting of
professional experts was organized with the aim of producing a consensus on identification and treatment
guidelines that will aid clinicians in caring for this unique patient population.
Methods: Experts from multiple disciplines in the fields of ADHD and FASD convened in London, United Kingdom,
for a meeting hosted by the United Kingdom ADHD Partnership (UKAP; www.UKADHD.com) in June 2015. The
meeting provided the opportunity to address the complexities of ADHD and FASD from different perspectives and
included presentations, discussions, and group work. The attendees worked towards producing a consensus for a
unified approach to ADHD and associated FASD.
Results: The authors successfully came to consensus and produced recommended guidelines with specific
regards to identification and assessment, interventions and treatments, and multiagency liaisons and care
management, highlighting that a lifespan approach to treatment needs to be adopted by all involved.
Included in the guidelines are: 1) unique ‘red flags’, which when identified in the ADHD population can
lead to an accurate associated FASD diagnosis, 2) a treatment decision tree, and 3) recommendations for
multiagency care management.
Conclusions: While clinically useful guidelines were achieved, more research is still needed to contribute to
the knowledge base about the diagnosis, treatment, and management of those with ADHD and associated
FASD.
Keywords: Attention deficit/hyperactivity disorder (ADHD), Fetal alcohol spectrum disorders (FASD), Co-morbid
or associated FASD, Treatment guidelines, Consensus, Interventions
* Correspondence: susan.young1@imperial.ac.uk
1Imperial College London, London, UK
2Broadmoor Hospital, West London Mental Health Trust, Crowthorne,
Berkshire, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Young et al. BMC Psychiatry  (2016) 16:324 
DOI 10.1186/s12888-016-1027-y
Background
Approximately 5 % of the population world-wide is
reported to have a diagnosis of attention deficit/hyperactiv-
ity disorder (ADHD) [1], a disorder often associated with
co-morbid conditions that can complicate identification
and treatment [2]; fetal alcohol spectrum disorders (FASD)
are among those conditions that are commonly found to
co-exist with ADHD [3]. There is an established knowledge
base with regards to identification and treatment guidelines
for ADHD, and similarly, yet to a lesser degree, for FASD;
there is also an increasing awareness and knowledge base
of individuals having both disorders concurrently. There
are not, however, formal guidelines for diagnosis, random-
ized controlled trials of any kind, or evidence-based treat-
ment plans for this unique group of individuals with
ADHD and associated FASD [4]. Therefore, this multi-
disciplinary meeting was organized to produce identifica-
tion and treatment guidelines for patients with ADHD and
associated FASD according to the clinical expertise and
knowledge among the attendees based upon consensus.
In this article we refer to the co-existence of ADHD and
FASD as—ADHD and associated FASD—and not FASD
with associated or co-morbid ADHD because: 1) most alco-
hol affected individuals present with and are initially evalu-
ated for attention and executive function deficits [3, 5]; 2)
management of ADHD symptoms in the FASD individual
is integral to treatment and may minimize the potential im-
pact of the common secondary disabilities associated with
FASD [3]; and 3) speculation remains as to the nature of
the relationship of the co-existing disorders with each other
[3, 6]. The authors recognize that current formal guidelines
for the management of ADHD symptoms do not account
for the implications of prenatal alcohol exposure in affected
individuals, thus the formulation of expanded guidelines for
management of ADHD and associated FASD is the focus
of this discussion. Firstly, we describe what is known about
ADHD and FASD separately and then we describe what is
known about the co-existing disorders. Next we discuss
how our collaborative efforts led to consensus. Lastly,
we present our recommended guidelines for clinicians,
with specific regards to: identification and assessment, in-
terventions and treatment, and multiagency liaisons and
management. Included are three pertinent case studies
that exemplify the need for individualized treatments
and services, which commonly extend beyond medical
care. A list of abbreviations can be found at the end
of the manuscript.
ADHD
ADHD is a childhood onset, diagnosable neurobiological
disorder with genetic and environmental origins [7]
characterized by pervasive behavioral symptoms of
hyperactivity, inattentiveness, and impulsivity that inter-
fere with functioning and development [8]. In 1968 the
American Psychiatric Association officially recognized
hyperkinetic impulse disorder, which has since been
renamed ADHD in the second edition of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-II).
Symptoms present relatively early in childhood and persist
over one’s lifespan for about half of individuals with child-
hood ADHD [9, 10]. A systematic review and meta-
regression analysis reported an overall worldwide-pooled
estimate of 5.29 % [11]. Structural brain MRI studies,
comparing individuals with ADHD with controls, report
overall reductions in brain volume of those having ADHD
and reveal the largest differences in cerebellar regions, the
splenium of the corpus callosum, total and right cerebral
volume, and right caudate; several frontal regions assessed
in two studies also showed large significant differences
[12]. In addition to academic and social impairments, chil-
dren with ADHD are at risk for other psychological disor-
ders and about half have additional behavioral disorders
[7, 13]. Meta-analyses of 42 international prison studies,
based on data derived from symptom-based clinical in-
struments, reported 30 % of youth offenders and 26 % of
adult offenders have clinically diagnosable ADHD [14].
Furthermore, the adult offenders had higher rates of coex-
isting psychopathology and greater impairment due to
mood, anxiety and personality disorders [15].
Clear diagnostic criteria for ADHD are listed in the Diag-
nostic and Statistical Manual of Mental Disorders, 5th edi-
tion, (DSM-5) [8] and the World Health Organization’s
International Statistical Classification of Diseases, 10th edi-
tion, (ICD-10) [16] (note that ADHD is the ICD-10 equiva-
lent of hyperkinetic disorder). While the criteria have not
changed from DSM-IV [17], DSM- 5 has updated the def-
inition of ADHD to more accurately characterize the ex-
perience of affected adults, and examples have been
included to illustrate the types of behavior children, older
adolescents, and adults with ADHD might exhibit. There is
a strong evidence base in the literature regarding guidelines
for identification, treatment, and management of individ-
uals with ADHD, and the authors advocate use of the
National Institute for Health Care Excellence (NICE)
2008 guidelines [18].
FASD
FASD is a non-diagnostic descriptive term referring to
the full range of diagnosable conditions caused by the
deleterious effects of prenatal alcohol exposure (PAE),
including neuropsychological, behavioral, and physical
abnormalities [19]. The range of clinical phenotypes
varies in severity and outcome depending on the level,
pattern, and timing of maternal alcohol consumption
[19, 20]. Fetal alcohol syndrome (FAS) was first described
in 1973 [21]. In 1996 the United States’ Institute of Medi-
cine delineated useful classification terms including FAS,
partial fetal alcohol syndrome (pFAS), alcohol related birth
Young et al. BMC Psychiatry  (2016) 16:324 Page 2 of 14
defects (ARBD), and alcohol related neuro-developmental
disorder (ARND) [22]. It wasn’t until 2000, however, that
the term FASD was officially introduced [23].
The implications of heavy PAE are long term and per-
vasive, affecting the individual, mother, family, and com-
munity throughout one’s lifespan [24–26]. FASD are
considered a “hidden disability” because most individuals
affected by PAE are not identified until adolescence or
adulthood, if at all [27]. Although FAS is estimated to
occur in 2 to 7 per 1000 live births in young children in
the United States, and up to 68 per 1000 in high-risk
populations [28, 29], FASD are more prevalent and may
occur in as many as 2–5 % of younger school children in
the US and some western European countries [30],
which means that as many as 6 to 16 million young chil-
dren in the US may have FASD, based upon the current
US population of 320 million [31]. Meta-analyses of chil-
dren and youth in a child-care system revealed a 6.0 %
pooled prevalence of FAS and a 16.9 % pooled prevalence
of FASD [32]. A recent study reported a significantly high
proportion (86.5 %) of FASD among foster and adopted
youth referred to a mental health center, which were pre-
viously mis- or undiagnosed [33]. Furthermore, a retro-
spective assessment of children in the United Kingdom
reported prenatal alcohol exposure rates of 34 % among
“looked after children” and 75 % among those awaiting
adoption [34]. Brain imaging techniques have shown
that PAE causes permanent structural alterations to the
brain, and reduced overall volume [35, 36]. Studies have
demonstrated damage to the corpus callosum, cerebellar
vermis, basal ganglia, as well as perislyvian, orbito-frontal,
and parietal brain regions of individuals with FASD [35].
Additionally, a review of individuals with FASD reported a
pooled prevalence of 90.9 % having abnormal peripheral
nervous system function results [37].
There is a high prevalence of co-morbid conditions in
individuals with FASD [37]. Long term studies report that
adolescents and young adults with FASD have major
problems with adaptive behavior, with high rates of dis-
rupted education (61 %), trouble with the law (60 %), con-
finement (50 %), inappropriate sexual behavior on
repeated occasions (49 %), and drug and alcohol related
problems (35 %) [26]. Deficits in adaptive functioning can
often help clinicians identify individuals with prenatal al-
cohol exposure [26]. Individuals with FASD present with
specific behavioral impairments that make them especially
vulnerable to manipulation. They are easily coerced into
producing false confessions thereby making them more
likely to become involved with the criminal justice sys-
tem [38]; and one study reported 35 % of individuals
with FASD have been in jail or prison at some point
[39].
The diagnostic criteria for FAS is well established in
the ICD-10 and DSM-5, but the diagnostic criteria for
PAE conditions other than FAS are less precise and
subject to considerable debate due to lack of available
published evidence [40]. Several FASD diagnostic ap-
proaches have been designed to promote best practices,
but accurate clinical diagnoses remain, for the most part,
to be made by expert clinicians who have wider experi-
ence with complex neurobehavioral findings. According to
the ICD-10 and DSM-5 diagnostic criteria sets, in the ab-
sence of confirmed PAE, the signs and symptoms of FAS
fall into three categories: 1) a characteristic pattern of fa-
cial anomalies (short palpebral fissure, smooth philtrum,
thin vermilion border of the upper lip); 2) evidence of
growth retardation (pre-and/or postnatal); and 3) evidence
of central nervous system (CNS) abnormalities [19–21].
While the presence of facial anomalies enables diagnosis
in some children with histories of heavy prenatal alcohol
exposure, most PAE affected individuals do not exhibit
obvious dysmorphology [41] and/or lack reliable PAE his-
tory [42], which greatly hinders identification. Although
useful for classification, the IOM’s terms are not listed as
diagnosable conditions in the ICD or DSM criteria sets.
DSM-5 has proposed a diagnostic criteria set for neurobe-
havioral disorder associated with prenatal alcohol expos-
ure (ND-PAE), but is not yet intended for clinical use. A
recent paper on FASD [43] (which thoroughly elucidates
the diagnostic terms and includes the proposed DSM-5
criteria on ND-PAE) and recent book on ARND [44], to-
gether explain why a more accessible diagnosis is needed.
Until the DSM-5 or ICD-11 have established criteria sets,
the authors advocate using the 2005 Canadian Guidelines
for the Diagnosis of FASD [20]. These guidelines focus
more on the neurobehavioral assessment over growth de-
ficiencies and recommend using a multidisciplinary ap-
proach to diagnosis [20].
ADHD and associated FASD
Individuals with histories of heavy PAE or ADHD are at
risk for a wide range of impairments including behavioral
and neuropsychological deficits [37, 45, 46]. Children with
a diagnosis of ADHD present with impairments similar to
those apparent in alcohol-exposed children especially with
regards to executive functioning and attention deficits
[47]. There are, however, clear distinctions between the
two groups; individuals with ADHD with PAE perform
worse on conventional tests sensitive to attentional prob-
lems and conduct disorder, compared with individuals
with FASD [46]. ADHD is the most common psychiatric
disorder diagnosed in children with PAE in the United
States at a rate of 41 % [48] and in individuals with FASD
world-wide at a rate of 48 % [49]. Given the range of a 2–
5 % prevalence rate of FASD in the US and some western
European countries and the 41–48 % prevalence rate of
co-occurring ADHD, we estimate the prevalence of
ADHD and associated FASD to be 0.8–2.4 % among
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children in the US and some western European coun-
tries. Although, because many affected individuals are
un-diagnosed, we speculate that the two disorders
occur together at far higher rates than estimates suggest.
Despite the depth of knowledge on the separate disorders
and an increasing amount on the concurrence, the exact
relationship between the two remains unclear and there is
a debate over whether or not the presentation necessarily
constitutes separate entities [3, 6, 25]. Furthermore,
evidence indicates that ADHD symptoms in individuals
identified with FASD may be a specific clinical phenotype
[3]. Understanding the relationship between the disorders
is complicated by the fact that ADHD is primarily defined
descriptively (without a clear etiology) and FASD are
primarily defined mechanistically (with a clear etiology).
The clinical quality of ADHD in children with FASD often
differs from that of children having only ADHD [50]; be-
havioral studies report exacerbated effects of having both
PAE and ADHD compared with alcohol exposure alone
[45]. The majority of individuals with PAE lack the phys-
ical and facial dysmorphology commonly associated with
FAS [41] and many lack reliable histories of PAE [42],
which further increases the difficulty in making a clear
diagnosis. According to the National Organization of Fetal
Alcohol Spectrum (NOFAS), most individuals affected
by FASD are often only identified ─ if at all─ subse-
quent to a referral for learning disabilities or for co-
occurring ADHD [27], likely resulting in many mis- or
undiagnosed individuals. In the absence of high quality
studies examining the relationship between ADHD and
FASD and reporting on effective treatments, the authors
have produced identification and treatment guidelines for
clinicians, based upon expert consensus.
Methods
Experts from multiple disciplines in the fields of ADHD
and FASD convened on the 27th of June 2015 in London,
United Kingdom, for a meeting hosted by United Kingdom
ADHD Partnership (UKAP; www.UKADHD.com). The
meeting included presentations with electronic slides, dis-
cussions, and group work; and was recorded and later tran-
scribed. Psychiatrists, neuro-developmental pediatricians,
psychologists, education experts, researchers, and others
having personal experience with the impact of ADHD and/
or FASD, engaged in lively thought provoking discussions
throughout the day, with the aim of reaching consensus.
The meeting commenced with five presentations
(including case studies) on the following topics, where
each was followed by a question and answer session:
 ADHD and FAS: The Clinical Presentation
 Alcohol Exposure and Risk for Development of FAS
 Psycho-pharmacotherapy Interventions for Co-morbid
ADHD/FAS
 Education Interventions for Co-morbid ADHD/FAS
 The Criminal Justice Perspective
Following the presentations, all attendees separated
into three breakout session groups (smaller subsets of
the meeting attendees) to produce a framework of guide-
lines with specific regards to:
 Identification and Assessment
 Interventions and Treatments
 Multiagency Liaisons and Care Management
The discussions during the breakout sessions were facil-
itated by group leaders and summarized by note takers.
The group leaders then presented their group’s framework
of guidelines in a feedback session to all the meeting
attendees for another round of discussion and debate. The
medical writer consolidated the meeting transcription,
electronic slide presentations, and breakout session notes
into the manuscript. Lastly, the meeting transcription and
manuscript were circulated to all authors for review to
ensure agreement and a final consensus for a unified ap-
proach to ADHD and associated FASD was reached.
Results
Discussion
The authors successfully produced identification and
treatment guidelines for children and adults with ADHD
and associated FASD, to aid clinicians in caring for this
unique patient population, and the results follow below.
Due to the nature of the co-existing disorders, it was
recognized that services beyond medical care are re-
quired for the vast majority of patients.
Identification and assessment guidelines
When considering the possibility of ADHD co-existing
with FASD it is essential to investigate, with hopes of
obtaining, an accurate and detailed PAE history. It is also
important to routinely screen for FASD when ADHD is
identified or for ADHD when FASD is identified; the
DSM-5 and ICD-10 criteria sets are to be utilized for
diagnosing ADHD and FAS, and we advocate the use of
the 2005 Canadian guidelines for diagnosing all other
FASD until the DSM-5 and ICD-11 criteria sets are fur-
ther established. It is important to recognize the unique
characteristics or ‘red flags’ that may be present in the
individual with ADHD, which may assist in the identifi-
cation of co-existing FASD. Prevalence rates of ADHD
are known to be high in certain high-risk populations
such as prisoners, ‘looked after’ children, adoptees, and
individuals born prematurely. Efforts should be made
among medical, social, educational, and criminal justice
services to increase awareness of the need for appropriate
referrals for individuals in these high-risk groups. They
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should be referred to suitable local pathways for either
ADHD or FASD, based upon their primary presenting
condition. It is recognized that individuals with subtle
presentation may fail to meet the threshold for ADHD and
are likely to be missed with this approach; ideally, the de-
velopment of locally based complex neuro-developmental
services is recommended. Neuro-developmental services
could help identify and further assess affected individuals,
which could potentially minimize the secondary health and
social disabilities associated with ADHD and FASD.
The clinician should carefully identify and assess
PAE history
Maternal alcohol use during pregnancy should be in-
cluded in a standard interview for those being assessed
for ADHD. The World Health Organization’s Alcohol
Use Disorders Identification Test offers a simple method
of screening for excessive drinking and assists in making
a brief assessment [51]. It is recognized that clinicians,
patients and their families may be uncomfortable with
this line of questioning; therefore it is recommended
that enquiries concerning possible PAE be incorporated
in the context of obtaining a detailed family history, in
order to ‘normalize’ the questioning for both the clin-
ician and the individual under assessment. Additionally,
it is recognized that mothers may find difficulty in
admitting retrospectively that their child suffered PAE,
possibly as a result of perceived stigma. It is also import-
ant to ascertain the accurate amount of alcohol consumed
during pregnancy—depending on the size and alcohol
content of the drink, two drinks per day could equate to
two or more units. Obtaining an accurate alcohol use his-
tory will likely depend upon the interviewer’s skill and
training. As a guide, the clinician should investigate typical
pre-pregnancy lifestyle factors including general drinking
behaviors, use of prescription medication, and other
drugs. As part of this investigation the clinician may
need to access historical records from social workers, mid-
wives, and/or obstetricians. The lack of honest and accur-
ate estimates of alcohol consumption combined with the
oft-times lack of availability of the mother [52] is problem-
atic and can result in large groups of potentially high-risk
individuals remaining unidentified. Best practice therefore
suggests that countries adopt standardized investigative
procedures to identify and track these potentially at risk
individuals and their families. Due to the sensitive nature
of obtaining an accurate history of drinking during preg-
nancy, an empathic, non-judgmental approach to ques-
tioning is essential.
ADHD or FASD history and additional screenings
If the child or adult has been previously diagnosed with
ADHD then the clinician should routinely screen for
FASD and likewise FASD for ADHD. A diagnosis of FAS
should be made according to DSM-5 and ICD-10 criteria
sets and all other FASD should be assessed using the
2005 Canadian guidelines. A diagnosis of ADHD should
be made according to DSM-5 and ICD-10 criteria sets,
utilizing standard screening and diagnostic tools: Conners’
Rating Scales; Swanson, Nolan, and Pelham-IV (SNAP-
IV); and ADHD Rating Scale-IV. It is recommended that
the affected individual be referred, when appropriate, to
neuro-developmental services for additional assessments
in adaptive behavioral functioning, executive function, and
communication abilities.
Unique characteristics of ADHD with associated FASD
We recognize a number of unique characteristics or ‘red
flags’, which when present in individuals with ADHD,
may assist in the identification of associated FASD.
These ‘red flags’ can be considered as potential risk fac-
tors for having FASD. Clinicians are to be alerted if any
of the following unique characteristics are identified in
patients with ADHD:
 Possible or confirmed history of maternal alcohol
consumption during pregnancy,
 Predominant presentation with inattentive subtype
of ADHD, in addition to some impulsive behaviors,
 Failure to respond to, or increased behavioral
disturbance when prescribed methylphenidate,
 Poor psychostimulant response in children with IQ
under 50,
 Physical indicators of FAS or pFAS, including
delayed growth and/or specific facial features
(e.g., smooth philtrum, thin upper lip, and small eye
openings), and/or a
 Lack of response to typical behavioral interventions.
Intervention and treatment guidelines
Treatments for ADHD and associated FASD require an
individualized approach, as do all neuro-psychiatric dis-
orders. Clinicians should refer for multi-modal assess-
ments (often involving parents, teachers, occupational
therapists, and speech and language therapists), when
necessary, to assist them in treatment plan development.
The Centers for Disease Control offers guidelines to ser-
vice providers in making referral decisions specific to indi-
viduals with FAS [41], but can be a good resource for
referral considerations for individuals with ADHD with
associated FASD. When developing the treatment plan
the primary rearing environment should be recognized
and evaluated because it has different modulating effects
on affected individuals. The following co-occurring prob-
lems must be considered as contributors to the clinical
presentation; early onset post-traumatic stress disorder
due to direct or indirect exposure to violence including
specific alcohol related violence, and/or reactive or
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disorganized attachment disorders due to problems with
adoptions or multiple care givers (as in sharing parenting
arrangements between foster and birth families). Further-
more, because a combination of non-pharmacological
and pharmacological treatments are most often
required when treating ADHD, it is recommended
that this also be the case for individuals with associ-
ated FASD—noting that pharmacological treatments
should ideally be administered secondary to non-
pharmacological (psychological and behavioral) ther-
apies. While treatments differ between ADHD with
and without associated FASD, the 2008 NICE treat-
ment guidelines for ADHD are mostly applicable to
this group and should be used as a basis on which to
build the treatment plan and the medication options
available for ADHD are to be considered in the con-
text of PAE. If other co-morbidites are unveiled
throughout the assessment process, then it will be ne-
cessary to modify the treatment plan. NICE guidelines
allow for treatment with medication after 5 years of
age following psychological and behavioral therapies
and state that medication can be considered as the
first option for individuals with a severe presentation
of ADHD. Individuals with ADHD and associated
FASD (where hyperactivity, rather than a sensory
seeking need, is a predominant feature) will likely be
categorized as having a severe presentation of ADHD
and therefore may be treated with medication as a first
option upon diagnosis. Because ADHD and associated
FASD affects individuals at a very young age with
symptoms persisting over their lifespan, it is crucial that
they are treated, monitored, and supported throughout
their entire life. Additionally, it is important to maintain a
non-judgmental attitude towards affected individuals and
their families while developing and delivering the suitable
treatment plan. We developed a treatment decision tree
(Fig. 1) unique to children, adolescents, and adults with
ADHD and associated FASD that outlines and supple-
ments our guidelines.
The clinician should administer the following
treatments
Non-pharmacological treatments for the family
Family support is usually necessary, and oftentimes special
support may be required for the birth mother, because she
may need therapy to cope with possible feelings of guilt
and shame relating to alcohol use during pregnancy.
Educating and encouraging the birth mother may result in
reduced or no alcohol use in subsequent pregnancies. It is
also important to recognize the particular needs of adop-
tive parents and additionally to recognize the ongoing im-
pact of the child’s condition on the family because they
may need support groups or respite services.
Non-pharmacological treatments for the child
Treatment should be delivered primarily via the parents
and/or care givers by educating them in healthcare and
child training strategies, and techniques about the best
ways to care for and help their child. It is important for
affected children, and especially for those with additional
co-existing learning difficulties, to be fully assessed. It
may be necessary to develop a formal individualized
educational plan to access additional services to address
the need for educational supports.
Non-pharmacological treatments for the adolescent and
adult
Treatment can be delivered directly to the individual.
With regards to treatment decisions, however, it must
be first established whether or not the individual has
the capacity to make such decisions and whether or
not it is appropriate to have the family involved as
part of a shared plan or agreement. Safeguarding is-
sues need to be taken into account when dealing with
children, adolescents, and vulnerable adults. These in-
dividuals are capable of attending and benefiting from
group treatment/therapy sessions. Symptoms and their
associated impairments can become more marked in
older children as they progress into adulthood, thus
key topics that should be included in therapy, group
or otherwise, are: risk taking behaviors, inappropriate
sexual behaviors, problem solving skills, social skills,
and sleep hygiene techniques. It is of high importance to
note that risk taking behaviors and problem-solving defi-
cits in combination with impulsivity may increase the risk
of suicide.
Pharmacological treatments when psychological and
behavioral interventions are inadequate
It is important to carefully monitor progress and meas-
ure the effects of non-pharmacological treatments
through goal-based outcomes. If the co-existing disor-
ders are still causing significant impairment, after a
short period of one to three months, then a progres-
sion to the use of medication should be made. It is rec-
ognized that family involvement with regular and
frequent follow-up visits are essential to successful
pharmacological treatment. If a child resides within a
chaotic family it will be especially necessary to assess
whether a responsible adult is correctly administering
the medication.
Pharmacological treatments following baseline
physiological tests
The need to physiologically assess the individual and
run baseline tests is emphasized as highly important
for this group. The NICE treatment guidelines for
ADHD recommend the monitoring of blood pressure,
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pulse, height, weight, and the investigation of cardio-
vascular history with an ECG prior to medication use.
The following additional baseline tests should ideally
be ordered, to investigate the possible damaging ef-
fects of PAE: full blood count (FBC), thyroid function
test (TFT), liver function test (LFT), blood sugar, fol-
ate, gamma-glutamyltransferase (GGT; a test specific
to alcohol, especially important for teenagers), blood
pressure, and renal function test (RFT); these baseline
tests should be repeated if indicated clinically. Add-
itionally, care should be taken to obtain a full clinical
seizure history, if indicated clinically.
Pharmacological treatments to improve attention and
reduce hyperactivity and impulsivity
Currently developed medication can treat the symptoms of
ADHD, but cannot cure the disorder. Medication can im-
prove attention and reduce hyperactivity and impulsivity,
thereby allowing the individual to effectively manage their
difficulties, access and engage with suitable therapies, and
build upon their skills. Management of the core symptoms
may improve learning, minimize their potential impact,
and ameliorate the common secondary disabilities associ-
ated with FASD. Case study 1 (see Fig. 2) reveals the com-
plex nature of the assessment process and demonstrates
Fig. 1 Treatment Decision Tree
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how a carefully managed treatment plan can have a posi-
tive impact on affected individuals.
Pharmacological treatments with careful regards to
dosage and side effects
The side effects of medication use, among individuals
with ADHD and associated FASD, may be similar when
compared with individuals with ADHD, but more marked
due to the abnormal physiological aspects of the disorder.
Some stimulant medications can lead to more pronounced
anxiety, appetite, and sleep problems; they may also affect
growth hormones and may increase the prevalence of tics.
The response to medication can be idiosyncratic and un-
predictable because some medications may cause a
regression of behavior. In particular, high doses of atomox-
etine (ATX) may cause liver damage, therefore low doses
are recommended initially. Before increasing a medication
dosage it is recommended that the non-pharmacological
strategies are revisited and additional assessments are
made to account for any under or misdiagnosed co-
existing conditions. The individual should be re-evaluated
and monitored frequently throughout the intervention
process.
Pharmacological treatments with careful regards to the
risks of developing an addictive disorder
Short-acting stimulants are typically trialed first in patients
with ADHD to examine tolerance before progressing to
Fig. 2 Case Study 1—Pharmacological Treatment
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long-acting stimulants. This treatment can be problematic,
however, in adolescents with ADHD and associated FASD
because short-acting stimulants may potentially contribute
to the development of addictive disorders during the teen-
age years. Therefore, long-acting/biphasic stimulants or
atomoxetine (which do not give an immediate ‘buzz’) are
recommended because they are less likely to contribute to
the development of an addictive disorder.
Multi-agency liasons and care management
The effects of ADHD and associated FASD are lifelong
and pervasive, affecting the individual, mother, family,
and community. Therefore, it is extremely important
that interventions are comprehensive, continue through-
out the lifespan, and extend beyond medical care to in-
clude when necessary: social, educational, mental health,
employment, and criminal justice services. These inter-
ventions are likely to be productive when service agencies
collaborate with each other. The coordinated efforts of
service professionals should support not only affected
individuals, but their families as well. In addition to multi-
agency collaboration, it is important that each agency
offers distinct services designed to enhance quality of life
and long term outcomes. While the non-pharmacological
treatments previously mentioned cover some of these
aspects, there are many additional services that may need
to be accessed and managed at different phases of life.
The clinician should make referrals for the
following services
Social services for the family
If there is suspected or confirmed PAE and/or subse-
quent failure to engage with professionals, social service
referrals for the mother and developing child may need
to start prior to birth. Because affected children often
display challenging behaviors, social service professionals
can offer parents, caregivers, and siblings, training and/
or support for managing those behaviors, thereby bol-
stering family resilience. Family resilience is also likely to
be enhanced with the provision of respite services and
group support. Social service professionals should rou-
tinely review the needs of the family, including possible
financial needs, in order to provide timely and compre-
hensive services, which is especially important during
key transition times.
Social services for the young child
Young children would benefit from preschool placements,
where staff have an understanding of FASD and ADHD,
and can offer an appropriate environment to meet the
developmental needs of the child; and may be referred for
specialized stimulating play therapy and/or other pre-
school services. It may be required that pediatric medical,
mental health, social care, and educational professionals
coordinate their services (with parental input) to ensure
coherent and consistent support. It is important to
recognize the potential need for intervention by local au-
thorities or the need for a referral to an adoption special-
ist. Given the high incidence of placement breakdown,
and the subsequent impact of repeated failure on the child
and care system, commissioning officers should carefully
evaluate the relative merits of foster and adoption
placements against more specialized and perhaps resili-
ent services. When children with ADHD and associated
FASD are separated from their birth mothers and moved
through the care system, they are often inaccurately iden-
tified as having insecure or disorganized attachment disor-
ders, instead of being accurately identified as having
developmental, emotional, and behavioral difficulties at-
tributed to PAE. In addition, safeguarding issues should be
assessed and, in cases of abuse and exploitation, child pro-
tection services should be informed and accessed.
Social services for the adolescent
Social services may need to be accessed because puberty
is a particularly vulnerable phase of development. Many
young people affected by PAE may crave friendship and
a sense of belonging, but often lack the skills required to
achieve these. Supported social groups may therefore as-
sist in establishing meaningful relationships with peers
within the local community, which is thought to be a pro-
tective factor in averting deterioration in mental health,
and enhance quality of life. It is important to recognize
breakdowns and/or transitions in living accommodations,
education placement and treatment plans for these young
adults. It is also important to recognize the increased risk
of drug and alcohol abuse or misuse during adolescence.
The clinician may have a key role regarding safeguarding
issues by screening for abuse and exploitation, and acces-
sing child protection services if necessary.
Educational services for the preschool child
Additional support for the child may be necessary starting
in preschool. It is important to recognize the need for
child friendly, age-appropriate tasks and activities. It is
also important that young children receive broad assess-
ments of needs across multiple measures, and particularly
in language comprehension. The pre-school and young
primary school child, and family, may benefit from
home-visits from educational services to help parents
to understand the developmental benefits of learning
through play, methods for encouraging and enhancing
verbal and non-verbal communication, and in man-
aging challenging behaviors.
Educational services for the primary school child
It is important to obtain a comprehensive assessment of
needs and functional analysis of behavior, and to
Young et al. BMC Psychiatry  (2016) 16:324 Page 9 of 14
consider the possible impact of deprivation and limita-
tions unique to these children. It may be necessary to
make a referral for the development of an individualized
education plan with track-able goals (key learning and de-
velopmental targets attainable within a specified time-
frame) to document progress. Education planning should
include input from students themselves, parents and/or
caregivers, and teaching professionals. The assessments
and individualized education plan are helpful in determin-
ing the student’s best learning environment (e.g., inclusive
mainstreaming or special education) and may be required
to access education supports and appropriate placement. It
is essential for all involved to recognize that these students
often benefit most from a strengths-based approach and
from differentiated learning. Teachers and educational psy-
chologists will most likely require training to develop rele-
vant assessments and educational strategies specific to this
population. Staff awareness, understanding, and compe-
tence are key factors in a student’s progress.
Teaching professionals need to consider not only the
curricular and staffing requirements of affected students,
but also their sensory and social needs. Teachers and
support staff need to identify the student’s possible barriers
to effective engagement with peers (e.g., social communica-
tion and an understanding of ‘friendship’), and provide
supportive environments in which social skills may be
developed or enhanced. Individuals having difficulty with
arousal and mood self-regulation may find mainstream
settings too overwhelming and may benefit from a
more supported special education setting. Nevertheless,
even severely affected individuals can be successfully
mainstreamed with support (see case study 2; Fig. 3).
Challenging behaviors and/or a disengagement from
learning often arise when students are not placed in the
appropriate setting. Teachers and support staff should as-
sess challenging behavior from a functional, rather than
judgmental, perspective and be sensitive to the potential
impact that their own responses may have on a student
when difficulties arise. Punitive measures are less likely to
be effective than strategies based on positive behavior
management.
Educational services for the adolescent and adult
Educational supports are likely needed when there are
breakdowns and/or transitions in placement in second-
ary school or higher education and when the individual
shows behavioral signs of being disengaged from school-
ing. Because school is a moderating influence, the prema-
ture cessation of formal learning is likely to elevate the
risk of offending behavior, which can result in a decline in
long term mental health. Furthermore, family resilience is
also negatively impacted by the school exclusion or place-
ment breakdown. Educational planners must therefore be
responsive to the dynamic nature of student’s individual
needs and make appropriate provisions.
Employment services
Affected teenagers and adults will likely require help in
finding and maintaining employment, but with proper
support can engage in meaningful employment. Employ-
ment services should be aimed at enhancing skill develop-
ment, thereby increasing job prospects and sustainable
engagement in work. Post-school transition plans should
consider the educational and developmental level (rather
than chronological age) of the young person. Affected in-
dividuals may require staged transitions into employment
via work experience, supported with mentors or job coa-
ches, and college link courses in order to fulfill their voca-
tional potential. The identification of specific barriers (e.g.,
in establishing effective work-place relationships) may be
more beneficial than the provision of generic support.
Criminal justice services
The clinician may have a role in helping affected children
or adults by recommending an appropriate representative
to interface with the criminal justice system and/or
by referring for the development of an identification
card indicating the presence of a disability that the affected
individual can present to criminal justice service personnel
if necessary. According to the National Organization on
Fetal Alcohol Syndrome, “The criminal justice system can
help FASD-affected individuals by: educating judges, law-
yers, and parole officers about the characteristics and be-
haviors of individuals with FASD, establishing a screening
and referral process for those with ADHD and FASD
who enter the juvenile justice or adult criminal justice
system, establishing/utilizing alternative sentencing pro-
grams for affected individuals who have committed non-
violent offenses, offering referral information for the
children of incarcerated women who may have been pre-
natally exposed to alcohol.” [27]. These affected individuals
should be diverted, whenever appropriate, into interven-
tional services with the goal of support and skill develop-
ment to improve functioning in society.
Case study 3 (see Fig. 4) illustrates how a failure to
recognize and diagnose FASD could result in a miscar-
riage of justice. People with FASD are likely to require
the services of a ‘registered intermediary’ in court to fa-
cilitate effective communication, and in some cases also
during police questioning. As a minimum, like young
persons with ADHD, they should have an ‘appropriate
adult’ present during police interviews in order to ensure
fairness and justice [53].
Consensus and Conclusions
Although more research is needed to identify, treat, and
manage affected individuals, the authors successfully
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came to a consensus for a more unified approach to
ADHD and associated FASD. The authors agreed that
there is a need to increase the number and training of
clinicians and to expand services for this unique popula-
tion. The authors also agreed upon the need to develop
complex neuro-developmental services that could help
identify and further assess affected individuals, and inter-
vention services that could help divert affected individuals
away from the criminal justice system, when appropriate.
It is likely that governmental support will be necessary in
the development of these services.
The most significant outcome of the collaborative ef-
forts amongst the multi-disciplinary professionals was the
production of clinically meaningful guidelines, based upon
consensus. Included in the guidelines are unique ‘red flags’,
which when identified in the ADHD population can lead
to an accurate associated FASD diagnosis, a treatment
decision tree, and recommendations for multi-agency care
management. Given the lifelong, pervasive nature of
the associated disorders, the authors’ emphasized that
a lifespan approach to treatment needs to be adopted
by all involved. The implementation of these guidelines
Fig. 3 Case Study 2—Secondary Education Provision
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has the potential of making a significant, positive impact
on affected individuals.
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